Beactica Therapeutics
PrivateLast Round
Grant
Feb 17, 2026
Total Funding Raised
$3.46M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Beactica Therapeutics operates in Healthcare & Life Sciences and is based in Uppsala. Its latest recorded funding round was a Grant round in February 2026.
Beactica Therapeutics is a precision medicine company that develops novel small molecule therapeutics to treat life-threatening cancers with significant unmet clinical need.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Beactica Therapeutics Comparables
Compare Beactica Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Degron Therapeutics | 83% | |
| Sprint Bioscience | 82% | |
| Captor Therapeutics S.A. | 81% |
For institutional investors. Book with your work email.
Beactica Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 17, 2026 | ||||
| VC Round | Mar 23, 2021 | ||||
| Grant | Jun 18, 2019 | ||||
| VC Round | Jun 4, 2019 | ||||
| VC Round | Aug 28, 2018 | ||||
Grant | Apr 18, 2018 |
For institutional investors. Book with your work email.
Beactica Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| European Innovation Council Fund | Grant |
| European Commission (Horizon Europe) | Grant |
| Almi Invest AB | VC Round |
| Vinnova | Grant, VC Round |
| Uppsala University Invest | VC Round |
| Swelife | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 26, 2026
Monthly visitors increased 79% MoM.
- Feb 17, 2026
Secured $3M in grant funding.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 6, 2026
On Oct 6th '26, Beactica Therapeutics AB develops BEA-28 alongside a biomarker-driven strategy to identify tumours most likely to respond, with combination strategies planned alongside checkpoint inhibitors in a non-mesothelioma high-unmet-need cancer and KRAS inhibitors in KRAS-driven cancers.
For institutional investors. Book with your work email.
Beactica Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Beactica Therapeutics's valuation, stock price, and market status.
Is Beactica Therapeutics a public or private company?
Beactica Therapeutics is a private company.
What is the current stock price of Beactica Therapeutics?
Beactica Therapeutics is a private company, so its shares have no public market price. Caplight tracks Beactica Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Beactica Therapeutics worth (valuation)?
Valuation information for Beactica Therapeutics is not publicly available.
Can I buy Beactica Therapeutics stock?
Beactica Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Beactica Therapeutics's last funding round?
Beactica Therapeutics's most recent funding round was Grant on February 17, 2026.
Who are the main investors in Beactica Therapeutics?
Key investors in Beactica Therapeutics include European Innovation Council Fund, Almi Invest AB.
Will Beactica Therapeutics IPO soon?
No public IPO plans have been announced for Beactica Therapeutics.
How can I track Beactica Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Beactica Therapeutics's shares on secondary markets.